SNAP out of it!

Most of us have ridden this thing down to 1.3 cents and back. Nothing has changed, be patient.

Was Dr. Thomas the one who wrote the article that was against DNA being used for researching racial medical differences? (Sorry, I cant seem to find the words to explain it better. Also don't have a link to the article.)

W2P,

From what I understand DNAP plans to provide Statinome and Ovanome as a service first (running the test themselves at first), and eventually to make the test available through other labs. From your prior post, I take it that they would have to meet FDA guidelines for each respectively (service and test).

Does the FDA have an adopted approval process regarding pharmacogentic predictive tests?

Has DNAP applied for FDA approval for Statinome and/or Ovanome?

DNAP's tests themselves do not cause any adverse reactions, but can aleviate a lot of pain, suffering, and in some cases save lives.

Getting FDA approval is an important first step before a company can begin marketing their test to pharma, health insurance, doctors, and patients. DNAP can't begin to market its predictive tests until we get FDA approval. Didn't the FDA stop Roche from marketing their dna test for a metabolizer? Does anyone know whether we have applied for FDA approval for Statinome and/or Ovanome?

Does anyone know whether the FDA has an approval guideline for a pharmacogenetic predictive test? (I think the Biometrics Coucil gave their recommendations, however, I don't know that an FDA approval process has been adopted.)

From the FDA website:

"FDA has streamlined its review process for medical products in recent years to help speed important new treatments to patients. For example, the average review time for an innovative new drug is now only 6 months, and some have been approved even faster."

News could come from a variety of DNAP fronts:

I personally haven't heard a status update on products for quite a while, and would love to get a newsletter updating us on all of DNAP's products in the pipeline and where they are at. (at least the ones we know about.) Here's a little reminder of all the DNAP fronts we could get some news about:

1. DNAP receives Association of Crime Lab Directors (ASCLD) certification

2. AncestryByDNA version 3.0 released (last I heard was due by the end of this year. I think 3.0 will be tremendously more interesting than 2.0)

3. Hair color, eye color, and/or skin tone added to existing Forensic DNAWhitness product. (they are in process of getting 1000 more DNA samples, so not likely eye color will happen soon.)

4. News about existing ADMIXMAP collaborative research efforts. (I'll throw the NYU immunosuppressant project here, even though that collaborations were announced prior to ADMIXMAP platform product announcement.)

5. New ADMIXMAP collaborative research partnerships.

6. An update on Statinome. (Product supposedly due in 2003.) Is this in clinical trials? Perhaps FDA approval! FDA approval on Statinome will start the launch sequence on the PPS.

7. An update on Ovanome. (Conflicting reports of when this is due. At stockholder meeting, they said 2004. In 10Q they indicated "sooner than we think.")

8. news on acquiring a drug pipeline, becoming a pharmaceutical company.

9. New research grant award.

10. Confirmation and clarification of our relationship with DNA Phenomics. (Perhaps combination of #8, #9, and/or #10 at the same time.)

11. Lucrative partnership or contract for forensic work. (wouldn't an FBI contract be nice?)

12. News of another high profile criminal case solved with the help of DNAP.

13. A lucrative partnership with a company interested in bringing one of our pharmaceutical products to market.

14. A new project/product that none of us are aware of. (More than likely a pharmacogenetic project.)

I can think of some more sources of news, but not any that would be likely to effect the PPS, so I'll stop here.

Please keep in mind that Ihub allows you to send private messages too. A lot of stuff being posted publicly really could be private messages. We had sixty messages since yesterday afternoon, many of which contained no substance. I'd like to see this board retain some of the quality that it used to have.

2nd Q income was at the low end of my expectations. But HOLY COW! Liabilities/costs were way up! About double what I expected. I hope some of those expenses are one-time-only factors. (such as the stock for officers.)

I don't think they will be offsetting their 3 million deficit (so far) any time soon.

I was also hoping for some updated news regarding the time frame of products, and whether they are still on course, or if we should expect delays.

Put me down for a buck on Aug. 22. You gotta love them odds.

I expect a late filing, most likely next week. They haven't put one out on time in a few reports.

The Moon, their final frontier, these are the voyages of a small company, DNAP. It's ongoing mission: to explore many new DNA samples, to seek out new pharmaciutical applications and pharmacogenetics products, to boldly go where no startups have gone before.

DNAP's exploration crew:
Captain Richard Gabriel
Chief Science Officer, Tony Frudakis
Chief Medical Officer, Hector Gomez
Chief Engineer, Monica Tamborini

Longs=Clingons
Day Traders=Romulans

Houston, we have .08! eom

I think DNA Phenomics will be a shell company for DNAP. DNA Phenomics has not received grant funding from Malaysia yet, and until it does, they must do whatever is required to get the grant funding. Someone jumped the gun. No contract with DNAP is needed until the funds are won. No announcement will be made until after. This is all of course, my speculative rambling, and isn't backed by any facts.

Basically, I think it means that the patent hasn't been approved yet.

My thoughts on DNA Phenomics are entirely speculative.

There is obviously a connection between DNAP and DNA Phenomics as uncovered by all of you who are much more diligent than I.
The purpose remains obscure, but DNA Phenomics is/will be offering research services that are DNAP services. ADMIXMAP is a DNAP proprietary product. Does DNA Phenomics have the throughput to do this research itself? or will they rely on DNAP's algorithms and processing equipment? The equipment is very expensive, why else would DNAP have made a pact with Orchid to get it. Can DNA Phenomics afford such equipment? I think it's highly unlikely.

I think that DNA Phenomics will be a shell company. Most probably to tap into Malaysian grant money. If the money is there, DNA Phenomics will do what it has to in order to qualify for the grant money. They may also obtain DNA samples from Malaysian people to test. However, those tests more than likely will be put through a machine in Sarasota Florida.

IMHO

It just goes to show that many of the people involved in forensics already know about DNAP, and what we can do. Let's face many in the forensics field must be very excited about this, and the orders must be coming in, and we are seeing cold cases getting a fresh new look around the country.

Dr. T on Thursday will open the eyes of a few hundred more in this field.

Cash flow neutral in 2nd Q? I doubt it. I think you are doing an injustice by increasing expectations beyond what is realistic. I know Im going to be happy about whatever figure that they show, because it will be an increase in revenue. However, DNAP's quarterly expenses run about 750K, and I strongly doubt that their revenues will break 500K. Who knows maybe I will be pleasantly surprised.

I personally predicted last quarter that 4th quarter this year they will finally break even.

Cosmic, you said, "The projects already in DNAP's pipeline (Diabetes, ACE inhibitors, immunology, etc.)"

Where did you hear about these projects? I am unfamiliar with their efforts on any of those you mentioned.

Thank you! A very realistic expectation. I worry at times that people get their expectations too high before 10K comes out, only to be disappointed.

Saying that DNAP is the only company that offers Admixmapping, is like saying Ford is the only company that offers Mustangs. Admixmap is a term that DNAP coined. Other companies can use allele frequency mapping.

It depends on how patient you are for .50. I don't think it will hit .50 based on 2nd quarter earnings, if that is what you are expecting to drive it there. What time frame did you have in mind?